Observers puzzled by delays in China's approval of BioNTech-Pfizer vaccine

Some believe Beijing may be concerned approval of the BioNTech shot could be interpreted as an acknowledgment that local shots are less effective than Western ones.

Related Keywords

China ,Beijing ,Taiwan ,Guangdong ,Jilin ,Hong Kong ,Wuhan ,Hubei ,Macau ,Chinese ,Guo Guangchang ,Joerg Wuttke ,Fosun Wu ,Brad Loncar ,Wu Yifang ,Seton Hall Huang ,Fosun Pharma ,Gao Fu ,Huang Yanzhong ,Cansino Biologics Inc ,European Union Chamber ,China Sinovac Biotech Ltd ,World Health Organization ,Taiwan Centers For Disease ,Shanghai Fosun Pharmaceutical Group Co ,Chinese Center ,Pfizer ,China National Medical Products Administration ,Fosun International ,Pfizer Inc ,Fosun International Ltd ,European Union ,Fosun Pharmaceutical Group ,Chief Executive Officer Wu Yifang ,Wall Street Journal ,National Medical Products Administration ,Chairman Guo Guangchang ,Taiwan Centers ,Disease Control ,Global Health Studies ,New Jersey ,Seton Hall ,Loncar Investments ,Sinovac Biotech ,Cansino Biologics ,Covid 19 ,Covid 19 Vaccines ,